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Abstract 
Background: Ara h2 sIgE serum levels improve the diagnostic accuracy for predicting peanut allergy, but the use of 
Ara h2 purified protein as a skin prick test (SPT), has not been substantially evaluated. The fraction of exhaled nitric 
oxide (FeNO) shows promise as a novel biomarker of peanut allergy. Reproducibility of these measures has not been 
determined. The aim was to assess the accuracy and reproducibility (over a time-period of at least 12 months) of SPT 
to Ara h2 in comparison with four predictors of clinical peanut allergy (Peanut SPT, Ara h2 specific Immunoglobulin E 
(sIgE), Peanut sIgE and FeNO).
Methods: Twenty-seven children were recruited in a follow-up of a prospective cohort of fifty-six children at least 
12 months after an open-labelled peanut food challenge. Their repeat assessment involved a questionnaire, SPT to 
peanut and Ara h2 purified protein, FeNO and sIgE to peanut and Ara h2 measurements.
Results: Ara h2 SPT was no worse in accuracy when compared with peanut SPT, FeNO, Ara h2 sIgE and peanut sIgE 
(AUC 0.908 compared with 0.887, 0.889, 0.935 and 0.804 respectively) for predicting allergic reaction at previous food 
challenge. SPT for peanut and Ara h2 demonstrated limited reproducibility (ICC = 0.51 and 0.44); while FeNO dem-
onstrated good reproducibility (ICC = 0.73) and sIgE for peanut and Ara h2 were highly reproducible (ICC = 0.81 and 
0.85).
Conclusions: In this population, Ara h2 SPT was no worse in accuracy when compared with current testing for the 
evaluation of clinical peanut allergy, but had—like peanut SPT—poor reproducibility. FeNO, peanut sIgE and Ara h2 
sIgE were consistently reproducible despite an interval of at least 12 months between the repeated measurements.
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Background
Peanut allergy can be a life threatening event and 
accounts for approximately two-thirds of all fatal 
food-induced anaphylaxis [1]. In a recent Australian 
population based study [2], the prevalence of peanut 
sensitisation [by skin prick testing (SPT)] in infants was 
6.4 %, with a prevalence of clinical allergy (confirmed by 
oral food challenge) of 2.9 %. Furthermore, clinical pea-
nut allergy resolves in up to 20 % of children [3] but the 
processes involved in resolution are not fully understood 
[4].
Current testing to confirm sensitisation to peanut 
includes SPT to peanut protein and specific immu-
noglobulin E (sIgE)  antibodies to peanut [5]. The gold 
standard for diagnosing clinical allergy is a double-blind 
placebo-controlled oral food challenge [6]. However, 
there is the associated risk of severe allergic reaction 
(including anaphylaxis), financial cost to health care (to 
provide beds and supervision), and finally time involved 
Open Access
Allergy, Asthma & Clinical Immunology
*Correspondence:  Joerg.Mattes@Newcastle.edu.au 
1 Experimental & Translational Respiratory Medicine Group, Hunter 
Medical Research Institute, University of Newcastle, Lookout Road, New 
Lambton, Newcastle, NSW 2305, Australia
Full list of author information is available at the end of the article
Page 2 of 9Percival et al. Allergy Asthma Clin Immunol  (2016) 12:35 
for patients, their families and health care professionals. 
To alleviate this, in clinical practice it is routine to con-
duct open-labelled food challenges [2, 7] and to exclude 
children at extremely low or high risk for clinical allergy 
from food challenge employing (a set of ) non-invasive 
biomarkers. For instance, the resulting size of SPT wheal 
to whole peanut antigen or levels of sIgE antibodies to 
peanut is thought to correlate with an increasing likeli-
hood of reaction [8, 9], but not with increasing severity of 
the reaction at food challenge [6]. While these tests con-
firm an allergy based on a significant clinical history, they 
do not suggest how severe the reaction will be on subse-
quent exposures. Monitoring these values over time may 
assist with identifying patients who are likely to outgrow 
their allergies (decreasing size of SPT wheal). However, 
as SPT is an operator driven test this type of deduction 
may at times be erroneous, placing children at risk of 
allergic reaction at a food challenge.
Prospectively measured levels of serum sIgE against 
the peanut component Ara h2 have been investigated 
and when used in combination with peanut SPT, found 
to improve the diagnostic accuracy and reduce the need 
for oral peanut challenge [5, 7]. Two studies published in 
2007 [10, 11] have investigated the use of Ara h2 purified 
protein as a SPT reagent, but there has been no further 
published data reporting on its use.
Fraction of exhaled nitric oxide (FeNO) is a non-
invasive marker that has been shown to correlate with 
allergic airways inflammation and IgE sensitisation [12]. 
Additionally, there appears to be enhanced prediction of 
peanut allergy prior to food challenge when combining 
measurement of FeNO with current testing (peanut SPT 
and Ara h2 sIgE) [7].
The primary aim of this study was to assess the accu-
racy of purified Ara h2 protein SPT in comparison with 
four predictors of peanut allergy (peanut SPT, peanut 
sIgE, Ara h2 sIgE and FeNO). The secondary aim was to 
assess the reproducibility (over a time-period of at least 
12 months) of Ara h2 SPT, in comparison with the same 
four predictors of peanut allergy, by following-up a popu-
lation of children studied previously [7].
Methods
Study population
Twenty-seven children were able to be recruited in fol-
low-up from a cohort of fifty-six children enrolled in 
an earlier prospective study [7] that had involved chil-
dren scheduled for open-labelled peanut food challenge 
by their paediatric allergist at a tertiary referral paedi-
atric allergy centre in Newcastle, Australia. Their food 
challenge in the initial study had been scheduled to (1) 
confirm a peanut allergy diagnosis, (2) assess for the pos-
sibility of acquired tolerance, (3) test for clinical reactivity 
in children who had not consumed peanut but were sen-
sitised, or (4) had significant parental concern and anxi-
ety [7]. Participants were excluded from the earlier study 
if their SPT to whole peanut extract was ≥10 mm [7].
The original cohort (of fifty-six children) included 
thirty-two participants with a history of IgE mediated 
reactions, including anaphylaxis, not within the previous 
12 months. Three participants who underwent food chal-
lenge in the original study had equivocal challenge results 
and were excluded from the data analysis.
Ethics and consent
The Hunter New England Health Human Research Eth-
ics Committee approved both studies. Informed written 
consent was obtained from all parents or guardians prior 
to entry into the study, and from children as appropri-
ate for their age. Participants from the earlier study were 
invited by telephone call from the Allergy Clinical Nurse 
Consultant to participate in this follow-up study.
Original cohort assessment
Prior to the food challenge, the original cohort (of fifty-
six children) was assessed in a pre-challenge clinic. This 
clinic included assessing personal atopy and family his-
tory of atopy by way of a modified version of a previ-
ously validated parental questionnaire [13, 14]. Allergic 
rhinitis was assessed using paediatric validated allergic 
rhinitis and its impact on asthma (ARIA) criteria [15], 
where classification is according to symptom duration 
(intermittent or persistent) and severity (mild or moder-
ate/severe). Each was then scored 1—intermittent mild, 
2—intermittent moderate/severe, 3—persistent mild 
or 4—persistent moderate/severe. Eczema was assessed 
based on any previous medical diagnosis, and current 
“active treatment” including any current management 
other than emollients. Visible eczema was scored using 
the validated SCORing Atopic Dermatitis (SCORAD) 
system [16].
Patients in the original cohort then underwent SPT 
which was performed on the volar surface of the patient’s 
forearm using standard whole peanut extract reagent, 
1:10 w/v (Stallergenes, Antony, France). A positive result 
was ≥3  mm determined by averaging maximal perpen-
dicular wheal diameters fifteen minutes after applying 
the lancet. Positive control was with histamine base, 
6 mg/mL (Stallergenes, Antony, France) and with a wheal 
≥3 mm indicating a valid test [17]. Negative control was 
glycerol saline. Later in the study, a small number were 
able to be skin prick tested with purified protein Ara h2 
(100 μg/mL in glycerol saline solution). The Ara h2 pro-
tein was sourced commercially from Protein Labs, San 
Diego, California, where it was purified from peanut 
extract.
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Serum was collected and analysed using ImmunoCAP 
250 system (Phadia, AB, Uppsala, Sweden) for peanut 
sIgE and Ara h2-specific IgE.
FeNO was measured according to the American Tho-
racic Society and European Respiratory Society (ATS/ERS) 
guidelines [18]. Online single-breath analysis (ECOMED-
ICS, Duernten, Switzerland) was used with the requirement 
of an expiratory flow rate of 50 mL/s for a minimum of 2-s 
during at least a 4-s expiration time. A flow limiter main-
taining constant minimum exhalation pressure of 5 cm H2O 
prevented nasal nitric oxide (NO) measurement. Measure-
ments were repeated until criteria were met (2 results within 
5 % or 3 within 10 %) and the mean was recorded.
The open-labelled food challenge to peanut was con-
ducted according to Australasian Society of Clinical 
Immunology and Allergy (ASCIA) food challenge pro-
tocol [19]. A medical officer, blinded to the results from 
the pre-challenge clinic, supervised all challenges. Chal-
lenges were declared successful if there was no reaction 
during the food challenge and throughout the following 
week with regular ingestion of peanut. Challenges were 
declared unsuccessful if they had (1) anaphylaxis [which 
was defined according to ASCIA guidelines [20] or (2) 
clinical allergy, not anaphylaxis (CANA) when they dem-
onstrated an IgE mediated reaction consistent with pub-
lished pre-defined objective criteria [21].
Follow‑up cohort assessment
The follow-up study assessment was conducted over a 
six-month period and ranged from fifteen to thirty-two 
months after the individual participant’s original assess-
ment. The assessment was conducted in the paediatric 
outpatients department of a tertiary children’s hospital 
and involved two stages—(1) undertaking the previously 
validated questionnaire [13, 14] (assessing the current 
degree of atopic disease and their family history of atopy) 
and —(2) SPT to whole peanut extract and purified Ara 
h2 protein, measuring FeNO, and blood collection to 
measure sIgE to peanut and Ara h2 (as described above).
Statistical methods
STATA 13.1 and GraphPad Prism 6.0 were used for sta-
tistical evaluation and graphical presentation. Participant 
clinical features are presented as medians with minimum 
and maximum values for continuous variables (due to 
non-normal distribution), and frequency and percentages 
for categorical variables. Differences in participant clinical 
features between groups (defined by the results of their 
open food challenge in the original study) were tested 
using Mann–Whitney two-tailed test for continuous vari-
ables and Fisher’s exact test for categorical variables.
Receiver Operator Characteristic (ROC) curves 
were produced in STATA 13.1 and used to assess the 
ability of each measure in predicting an allergic reaction 
to peanuts. The area under the curve (AUC) is a sum-
mary measure of the sensitivity and specificity of the 
measure for all possible cut points.
Reproducibility was assessed using repeatability coeffi-
cient (CR) (calculated using Bland–Altman test in Graph-
Pad Prism) and the Intra-class Correlation Coefficient 
(ICC) was calculated using a one-way random effects 
model in STATA 13.1.
Results
Participant clinical features
The median time between the original and follow-up 
measurements was 2.2  years. The clinical features are 
outlined in Table  1. There were no significant differ-
ences when comparing the follow-up cohort with those 
who did not return for follow-up. (Additional file  1: 
Table S1).
Table 1 Participant clinical features of  the follow-up 
cohort
One patient had an equivocal result at challenge and was excluded from the 
analysis
AR allergic rhinitis; SCORAD SCORing Atopic Dermatitis; CANA clinical allergy not 
anaphylaxis; SPT skin prick test; sIgE serum-specific IgE; FeNO fraction of exhaled 
nitric oxide
a  For determination of rhinitis severity, see ‘‘Methods’’ section
b  Only 22 individuals in the follow-up cohort were able to perform FeNO
Follow‑up (n = 26)
Age (years) Median (min, max) 9.4 (4.1, 17.8)
Sex (%) Males 18 (69)
Parental smokers (%) Total 3 (12)
Previous adrenaline required 
(%)
Total 6 (23)
Other food allergy (%) Total 11 (42)
Allergic rhinitis (%) Total 17 (65)
AR severity for those with 
AR—max = 4a
Median (min, max) 4 (1, 4)
Eczema ever (%) Total 22 (85)
Eczema active treatment (%) Total 12 (46)
SCORAD for those with visible 
eczema
Median (min, max) 10.9 (3.0, 28.9)
Asthma ever (%) Total 17 (65)
Current preventer (%) Total 12 (46)
Current reliever (%) Total 15 (58)
Anaphylaxis in challenge (%) Total 5 (19)
CANA in challenge (%) Total 9 (35)
No allergy in challenge (%) Total 12 (46)
Ara h2 SPT (mm) Median (min, max) 3.8 (0.0, 9.0)
Peanut SPT (mm) Median (min, max) 6.3 (0.0, 13.0)
Ara h2 sIgE (kU/L) Median (min, max) 0.66 (0.00, 22.10)
Peanut sIgE (kU/L) Median (min, max) 0.99 (0.01, 35.60)
FeNO (p.p.b)b Median (min, max) 24.3 (2.7, 119.2)
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Clinical features of follow up cohort
In the follow-up cohort there were statistically sig-
nificant differences between the successful [no clinical 
allergy (CA) at food challenge] and unsuccessful (CA at 
food challenge) groups in regards to age, male sex ratio, 
previous adrenaline usage, and current use of a preven-
ter for asthma (Table 2). The patients without CA were 
younger (P value 0.015, Table 2). There were more males 
in the group of children without CA (P value 0.036, 
Table 2). Previous adrenaline usage in the CA group was 
higher (P value 0.017, Table  2). There were more par-
ticipants currently using a preventer for asthma in the 
group of children without CA (P value 0.045, Table  2). 
As expected, children with CA did not have exposure 
to peanuts subsequent to the challenge test (<0.0001, 
Table 2). Interestingly, two children who were described 
as tolerant (no CA at food challenge) in the original 
study have subsequently developed symptoms of food 
allergy after eating peanut subsequent to the original 
study and as such now avoid eating peanut. All other 
clinical features across the two groups did not reach sta-
tistical significance for difference.
Data availability
Data for the peanut SPT were available for all twenty-
seven individuals at the two time points. Only twelve 
individuals from the original group had data available for 
Ara h2 SPT, while twenty-seven individuals from the fol-
low-up group had data available for Ara h2 SPT. Data for 
FeNO were available for twenty individuals at the two 
time points. Seven children had data missing from one 
or both time points due to being unable to perform sin-
gle breath measurement of FeNO. Data were also avail-
able for peanut sIgE and Ara h2 sIgE for all twenty-seven 
individuals at the two time points. Due to an equivocal 
result in their challenge in the original study, one indi-
vidual was excluded from the analysis of the follow-up 
cohort.
Accuracy of Ara h2 SPT at predicting clinical outcome
There was a statistically significant difference between 
groups for Ara h2 SPT wheal size (P value 0.0001, Table 2). 
This compared with peanut SPT (P value 0.0004, Table 2), 
Ara h2 sIgE (P value <0.0001, Table  2), peanut sIgE (P 
value 0.0073, Table 2) and FeNO (P value 0.0018, Table 2).
Table 2 Follow-up cohort – divided by clinical allergy or not at food challenge in original study
One patient had equivocal result at food challenge and was therefore excluded from the analysis
Italics indicate statistical significance P < 0.05
AR allergic rhinitis; No CA no clinical allergy; CA clinical allergy; SCORAD SCORing Atopic Dermatitis; CANA clinical allergy not anaphylaxis; SPT skin prick test; sIgE 
serum-specific IgE; FeNO fraction of exhaled nitric oxide 
a  For determination of rhinitis severity, see ‘‘Methods’’ section
b  Following the successful challenge, two children subsequently developed symptoms at home after eating peanut and now avoid eating peanut
c  Only 9 individuals in the No CA group were able to perform FeNO, while 12 individuals in the CA group were able to perform FeNO
No CA n = 12 CA n = 14 P value
Age (years) Median (min, max) 6.8 (4.1, 15.9) 13.6 (4.5, 17.8) 0.015
Sex (%) Males 11 (92) 7 (50) 0.036
Parental smokers (%) Total 1 (8) 2 (14) 1.000
Previous adrenaline required (%) Total 0 (0) 6 (43) 0.017
Other food allergy (%) Total 6 (50) 5 (36) 0.692
AR (%) Total 9 (75) 8 (57) 0.429
AR severity for those with AR—max = 4a Median (min, max) 4 (1, 4) 3 (1, 4) 0.698
Eczema ever (%) Total 12 (100) 10 (71) 0.478
Eczema active treatment (%) Total 7 (58) 5 (36) 0.431
SCORAD for those with visible eczema Median (min, max) 19.2 (3.0, 28.9) 7.4 (3.4, 24.4) 0.460
Asthma ever (%) Total 9 (75) 8 (57) 0.429
Current preventer (%) Total 8 (67) 3 (21) 0.045
Current reliever (%) Total 8 (67) 7 (50) 0.453
Further exposure to peanut since challenge (%) Total 12 (100 %) 0 (0 %) <0.0001
Still eating peanuts at time of follow-up (%)b Total 10 (83 %) 0 (0 %) <0.0001
Ara h2 SPT (mm) (min, max) Median (min, max) 2.3 (0.0, 5.0) 6.5 (2.0, 9.0) 0.0001
Peanut SPT (mm) (min, max) Median (min, max) 4.0 (0.0, 8.5) 8.0 (5.0, 13.0) 0.0004
Ara h2 sIgE (kU/L) Median (min, max) 0.08 (0.00, 4.79) 2.21 (0.41, 22.1) <0.0001
Peanut sIgE (kU/L) Median (min, max) 0.31 (0.01, 35.60) 2.84 (0.32, 23.3) 0.0073
FeNO (p.p.b)c Median (min, max) 9.6 (2.7, 40.0) 42.1 (15.2, 119.2) 0.0018
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Clinical features of follow‑up cohort stratified for severity 
of clinical allergy
In the follow-up cohort, when the CA group was divided 
into subgroups of children with anaphylaxis or clinical 
allergy not anaphylaxis (CANA) based upon the result 
of their food challenge, there were significant differences 
between the groups in regards to age and previous adren-
aline usage (Table  3). Median age was 16.0  years in the 
anaphylaxis group compared to 10.9 years in the CANA 
group (P value 0.029, Table 3). Previous adrenaline usage 
in the anaphylaxis group was higher than the CANA 
group (P value 0.003, Table 3). All other clinical features 
across the two groups did not reach statistical signifi-
cance for difference.
Accuracy of Ara h2 SPT at predicting severity of reaction 
at challenge
When stratifying the clinical allergy group by severity of 
reaction at challenge (CANA or anaphylaxis), Ara h2 SPT 
did not show ability to differentiate between the groups 
(P value 0.541, Table 3). This compared with peanut SPT, 
Ara h2 sIgE, peanut sIgE and FeNO (P values between 
0.227 to 0.968).
Accuracy of Ara h2 SPT at predicting clinical outcome—
Allergy
The AUC for Ara h2 SPT predicting allergy was 0.908, 
which compared with the AUC for peanut SPT, Ara h2 
sIgE, peanut sIgE, and FeNO for predicting allergy (0.887, 
0.935, 0.804 and 0.889 respectively, Fig. 1).
Accuracy of Ara h2 SPT at predicting clinical outcome—
Anaphylaxis
The AUC for Ara h2 SPT predicting anaphylaxis was 
0.738. This compared with the AUC for peanut SPT, Ara 
h2 sIgE, peanut sIgE and FeNO for predicting anaphy-
laxis (0.638, 0.857, 0.791 and 0.763 respectively. Figure 2).
Reproducibility
Reproducibility for Ara h2 SPT was limited [ICC = 0.44 
and CR value −2.0 (Table 4)]. Peanut SPT reproducibility 
was also limited [ICC = 0.51 and CR value 0.85 (Table 4)]. 
Reproducibility was higher for FeNO [ICC  =  0.73 and 
CR value −8.2 (Table  4)]. Finally, reproducibility was 
highest for Ara h2 sIgE [ICC =  0.85 and CR value 0.03 
(Table  4)] and Peanut sIgE [ICC  =  0.81 and CR value 
−0.10 (Table 4)].
Table 3 Follow-up cohort – divided by severity of clinical allergy at food challenge in original study
Italics indicate statistical significance P < 0.05
AR allergic rhinitis; SCORAD SCORing Atopic Dermatitis; CANA clinical allergy not anaphylaxis; SPT skin prick test; sIgE serum-specific IgE; FeNO fraction of exhaled nitric 
oxide
a  For determination of rhinitis severity, see ‘‘Methods’’ section
b  Only 7 individuals in the CANA group were able to perform FeNO, while all 5 individuals in the anaphylaxis group were able to perform FeNO
CANA (n = 9) Anaphylaxis n = 5 P value
Age (years) Median (min, max) 10.9 (4.5, 17.8) 16.0 (14.0, 17.4) 0.029
Sex (%) Males 3 (33) 4 (80) 0.266
Parental smokers (%) Total 2 (22) 0 (0) 0.506
Previous adrenaline required (%) Total 1 (11) 5 (100) 0.003
Other food allergy (%) Total 4 (44) 1 (20) 0.580
AR (%) Total 5 (56) 3 (30) 1.000
AR severity for those with AR—max = 4a Median (min, max) 4 (2, 4) 3 (1, 4) 0.750
Eczema ever (%) Total 7 (78) 3 (60) 0.580
Eczema active treatment (%) Total 4 (44) 1 (20) 0.580
SCORAD for those with visible eczema Median (min, max) 7.4 (3.4, 24.4) 0.0 (0.0, 0.0) N/A
Asthma ever (%) Total 5 (56) 3 (60) 1.000
Current preventer (%) Total 2 (22) 1 (20) 1.000
Current reliever (%) Total 5 (56) 2 (40) 1.000
Ara h2 SPT (mm) (min, max) Median (min, max) 7.0 (2.0, 8.0) 5.0 (3.5, 9.0) 0.541
Peanut SPT (mm) (min, max) Median (min, max) 8.0 (5.5, 12.5) 6.0 (5.0, 13.0) 0.968
Ara h2 sIgE (kU/L) Median (min, max) 1.15 (0.41, 14.50) 5.02 (0.80, 22.10) 0.227
Peanut sIgE (kU/L) Median (min, max) 1.49 (0.32, 23.30) 3.88 (1.01, 21.80) 0.240
FeNO (p.p.b)b Median (min, max) 28.3 (15.2, 119.2) 55.1 (15.4, 79.5) 0.631
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Fig. 1 ROC curves for predicting allergy. a Ara h2 SPT and Peanut SPT 
for predicting allergy, b Ara h2 sIgE and Peanut sIgE for predicting 
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Fig. 2 ROC curves for predicting anaphylaxis. a Ara h2 SPT and 
Peanut SPT for predicting anaphylaxis, b Ara h2 sIgE and Peanut sIgE 
for predicting anaphylaxis, c FeNO predicting anaphylaxis
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Discussion
This study demonstrates that Ara h2 SPT had similar 
accuracy to Peanut SPT, FeNO, Peanut sIgE, and Ara 
h2 sIgE at predicting allergic reaction at food challenge. 
While the accuracy of Ara h2 SPT was also similar with 
Peanut SPT, FeNO, Peanut sIgE and Ara h2 sIgE at pre-
dicting severity of reaction at food challenge, the AUC 
for that question is too low to be clinically useful. Larger 
population numbers would need to be studied to deter-
mine appropriate thresholds of Ara h2 SPT for diagnosis 
of peanut allergy or anaphylaxis.
To further clarify the utility of FeNO at predicting 
clinical allergy, we re-calculated the area under the ROC 
curve after excluding patients with a history of asthma 
but it remained unchanged (0.90). We acknowledge that 
this analysis is based on small numbers and future studies 
are required to confirm our observations.
Overall the accuracy of all tests for predicting allergic 
reaction at food challenge was higher than that previ-
ously reported [5, 7]. It is possible that a selection bias 
contributed to this result because only 48 % of the origi-
nal cohort participated in the follow-up visit despite our 
very best recruitment efforts. Everyone who participated 
in the follow up study lived within 50 km of the research 
centre, while the original study included participants 
from up to 250  km away from the research centre pro-
viding some clue as why recruitment may have been less 
successful. It could be hypothesised that those with per-
sisting allergy were more likely to return, as they are likely 
to have ongoing contact with the clinical team (some of 
whom were involved in the research) or having persisting 
allergy may make them more likely to contribute with the 
desire of improving diagnosis and management of peanut 
allergy. Thus in clinical practice all tests can be expected 
to have a lower predictive value than found in this study 
due to a regression to the mean phenomenon [22].
This study has demonstrated relatively poor reproduc-
ibility for both Ara h2 SPT and peanut SPT. This possi-
bly relates to different operators performing the SPT in 
each cohort as would commonly happen in clinical prac-
tice. The ASCIA SPT manual highlights the likelihood of 
operator dependant technique significantly affecting SPT 
results [17]. Another possible cause for this poor repro-
ducibility may be due to changes in SPT size related to 
further exposure to peanut, for instance by inclusion 
into regular diet or by accidental exposures. However, 
we did not observe such great variability in sIgE. Recent 
research on the natural history of SPT would suggest that 
those with persisting clinical allergy would have increas-
ing SPT wheal size, while those with resolved clinical 
allergy would have decreased [23].
Despite the poor reproducibility of both Ara h2 SPT 
and peanut SPT, this study has demonstrated high levels 
of reproducibility for FeNO, and for Ara h2 sIgE and pea-
nut sIgE serum levels. The excellent reproducibility of the 
sIgE results is likely contributed to by the lack of poten-
tial variation in operator technique affecting the serum 
sIgE result. A significant limitation remains the small 
population and that it may not be representative of the 
true value in the total population.
Two results of interest relate to the participants who 
appear to have lost tolerance to peanut after a suc-
cessful challenge in the original study. While one par-
ticipant’s peanut and Ara h2 SPT and sIgE results have 
decreased compared to the original challenge, the other 
participant’s peanut and Ara h2 SPT and sIgE results 
have increased. These seemingly contradictory results do 
not provide insight into why these two participants have 
developed symptoms of allergy after successful challenge 
(and therefore presumed tolerance) in the original study. 
While it is known that peanut sIgE tends to increase in 
children with persisting peanut allergy with repeated 
exposure to peanut [24], there is no published data of the 
natural history of peanut sIgE or Ara h2 sIgE results in 
children previously sensitised to peanut whose clinical 
allergy has resolved.
An obvious weakness of this study is the time that has 
passed since the food challenge with no repeat conducted 
on the second visit. Therefore we cannot be certain if 
each individual is still allergic based upon that original 
challenge. Those with unsuccessful challenges reported 
no further accidental exposures since the challenge, and 
all but two children who had successful challenges were 
continuing to eat peanut in their diet regularly. This 
Table 4 Reproducibility of tests










Subgroup assessment (median & min, max) 6.5 (0.0, 10.0) 6.3 (0.0, 9.0) 32.5 (4.6, 170.5) 0.35 (0.00, 17.90) 0.90 (0.01, 31.60)
Repeat assessment (median & min, max) 3.5 (0.0, 7.5) 6.3 (0.0, 13.0) 26.6 (5.2, 119.2) 0.66 (0.00, 22.10) 0.99 (0.01, 35.60)
P value 0.039 0.170 0.332 0.974 0.259
CR value (95 % limits of agreement) −2.0 (−8.0, 3.9) 0.85 (−4.9, 6.6) −8.2 (−59, 42) 0.03 (−6.1, 6.2) −0.10 (−10.9, 10.7)
ICC value (95 % CI) 0.44 (0.00, 0.90) 0.51 (0.23, 0.80) 0.73 (0.51, 0.94) 0.85 (0.75, 0.96) 0.81 (0.68, 0.95)
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unfortunately does not help clarify their current allergy 
status. However, with no further clinical indication for 
food challenge arising in that period, we did not believe 
that a repeat food challenge at that time would have been 
ethically sound in this cohort of children.
Another limitation is the use of open challenges in the 
original study. While double-blind placebo-controlled 
food challenges are the gold standard for diagnosing food 
allergy [6], in clinical practice, open-labelled food chal-
lenges are routinely used [2, 7]. In the original study [7], 
to help minimise the chance of false positive results, out-
comes were designated based upon pre-defined objective 
criteria [5, 25, 26], as participants were recruited sequen-
tially from a list of children referred clinically for open-
labelled food challenge at a tertiary referral paediatric 
allergy centre to alleviate the lack of a placebo-controlled 
challenge [7].
Conclusion
In summary, Ara h2 SPT was no worse in accuracy when 
compared with current testing for the evaluation of 
peanut allergy in this population of children. SPT with 
purified Ara h2 protein and peanut protein in this study 
demonstrate poor reproducibility and further studies 
could help determine inter-and intra-operator variability. 
FeNO demonstrated high accuracy and good reproduc-
ibility. Finally, peanut and Ara h2 sIgE collected in this 
study demonstrate high accuracy and excellent reproduc-
ibility over time, reaffirming the utility of these markers 
in assessing peanut allergy.
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